Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 637

1.

Donepezil treatment and Alzheimer disease: can the results of randomized clinical trials be applied to Alzheimer disease patients in clinical practice?

Tinklenberg JR, Kraemer HC, Yaffe K, Ross L, Sheikh J, Ashford JW, Yesavage JA, Taylor JL.

Am J Geriatr Psychiatry. 2007 Nov;15(11):953-60.

PMID:
17974866
[PubMed - indexed for MEDLINE]
2.

Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer's disease.

Mucha L, Shaohung S, Cuffel B, McRae T, Mark TL, Del Valle M.

J Manag Care Pharm. 2008 Jun;14(5):451-61.

PMID:
18597574
[PubMed - indexed for MEDLINE]
Free Article
3.

Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost-effectiveness.

Wolfson C, Oremus M, Shukla V, Momoli F, Demers L, Perrault A, Moride Y.

Clin Ther. 2002 Jun;24(6):862-86; discussion 837. Review.

PMID:
12117079
[PubMed - indexed for MEDLINE]
4.

Defining treatment response to donepezil in Alzheimer's disease: responder analysis of patient-level data from randomized, placebo-controlled studies.

Burns A, Yeates A, Akintade L, Del Valle M, Zhang RY, Schwam EM, Perdomo CA.

Drugs Aging. 2008;25(8):707-14.

PMID:
18665662
[PubMed - indexed for MEDLINE]
5.

Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial.

Feldman H, Gauthier S, Hecker J, Vellas B, Xu Y, Ieni JR, Schwam EM; Donepezil MSAD Study Investigators Group.

Int J Geriatr Psychiatry. 2005 Jun;20(6):559-69.

PMID:
15920715
[PubMed - indexed for MEDLINE]
7.

Response to rivastigmine or donepezil in Alzheimer's patients with symptoms suggestive of concomitant Lewy body pathology.

Touchon J, Bergman H, Bullock R, Rapatz G, Nagel J, Lane R.

Curr Med Res Opin. 2006 Jan;22(1):49-59. Erratum in: Curr Med Res Opin. 2006 Aug;22(8):1451.

PMID:
16393430
[PubMed - indexed for MEDLINE]
8.

Safety and tolerability of donepezil at doses up to 20 mg/day: results from a pilot study in patients with Alzheimer's disease.

Doody RS, Corey-Bloom J, Zhang R, Li H, Ieni J, Schindler R.

Drugs Aging. 2008;25(2):163-74.

PMID:
18257603
[PubMed - indexed for MEDLINE]
9.

Effect of donepezil in patients with Alzheimer's disease previously untreated or treated with memantine or nootropic agents in Germany: an observational study.

Klinger T, Ibach B, Schoenknecht P, Kamleiter M, Silver G, Schroeder J, Mielke R.

Curr Med Res Opin. 2005 May;21(5):723-32.

PMID:
15969871
[PubMed - indexed for MEDLINE]
10.

A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients.

Mohs RC, Doody RS, Morris JC, Ieni JR, Rogers SL, Perdomo CA, Pratt RD; "312" Study Group.

Neurology. 2001 Aug 14;57(3):481-8. Erratum in: Neurology 2001 Nov 27;57(10):1942.

PMID:
11502917
[PubMed - indexed for MEDLINE]
11.

Cognitive, global, and functional benefits of donepezil in Alzheimer's disease and vascular dementia: results from large-scale clinical trials.

Passmore AP, Bayer AJ, Steinhagen-Thiessen E.

J Neurol Sci. 2005 Mar 15;229-230:141-6. Epub 2005 Jan 6.

PMID:
15760632
[PubMed - indexed for MEDLINE]
12.

Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease.

Geldmacher DS, Provenzano G, McRae T, Mastey V, Ieni JR.

J Am Geriatr Soc. 2003 Jul;51(7):937-44.

PMID:
12834513
[PubMed - indexed for MEDLINE]
13.

A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD.

Winblad B, Engedal K, Soininen H, Verhey F, Waldemar G, Wimo A, Wetterholm AL, Zhang R, Haglund A, Subbiah P; Donepezil Nordic Study Group.

Neurology. 2001 Aug 14;57(3):489-95.

PMID:
11502918
[PubMed - indexed for MEDLINE]
14.

Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada.

O'Brien BJ, Goeree R, Hux M, Iskedjian M, Blackhouse G, Gagnon M, Gauthier S.

J Am Geriatr Soc. 1999 May;47(5):570-8.

PMID:
10323651
[PubMed - indexed for MEDLINE]
15.

Effects of donepezil on neuropsychiatric symptoms in patients with dementia and severe behavioral disorders.

Cummings JL, McRae T, Zhang R; Donepezil-Sertraline Study Group.

Am J Geriatr Psychiatry. 2006 Jul;14(7):605-12.

PMID:
16816014
[PubMed - indexed for MEDLINE]
16.

Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial.

Seltzer B, Zolnouni P, Nunez M, Goldman R, Kumar D, Ieni J, Richardson S; Donepezil "402" Study Group.

Arch Neurol. 2004 Dec;61(12):1852-6. Erratum in: Arch Neurol. 2005 May;62(5):825.

PMID:
15596605
[PubMed - indexed for MEDLINE]
17.

A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer's disease in outpatients treated with donepezil.

Finkel SI, Mintzer JE, Dysken M, Krishnan KR, Burt T, McRae T.

Int J Geriatr Psychiatry. 2004 Jan;19(1):9-18.

PMID:
14716694
[PubMed - indexed for MEDLINE]
18.

Donepezil treatment in severe Alzheimer's disease: a pooled analysis of three clinical trials.

Winblad B, Black SE, Homma A, Schwam EM, Moline M, Xu Y, Perdomo CA, Swartz J, Albert K.

Curr Med Res Opin. 2009 Nov;25(11):2577-87. doi: 10.1185/03007990903236731.

PMID:
19735164
[PubMed - indexed for MEDLINE]
19.

Drug persistency patterns for patients treated with rivastigmine or donepezil in usual care settings.

Mauskopf JA, Paramore C, Lee WC, Snyder EH.

J Manag Care Pharm. 2005 Apr;11(3):231-51.

PMID:
15804207
[PubMed - indexed for MEDLINE]
Free Article
20.

Representation of patients with dementia in clinical trials of donepezil.

Gill SS, Bronskill SE, Mamdani M, Sykora K, Li P, Shulman KI, Anderson GM, Hillmer MP, Wodchis WP, Rochon PA.

Can J Clin Pharmacol. 2004 Fall;11(2):e274-85. Epub 2004 Dec 15.

PMID:
15604527
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk